Electrolyte State in Patients With COVID-19

Electrolyte Imbalance Clinical Trial

Official title:

Electrolyte State in Patients With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04539834
• Other study ID #: (ZU-IRB#: 6328-23-8-2020)
• Status: Completed
• Start date: May 1, 2020
• Est. completion date: October 30, 2021

Study information

• Verified date: November 2021
• Source: Zagazig University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Initial case reports and cohort studies have described many clinical characteristics of patients with coronavirus disease 2019 (COVID-19), an emerging infectious disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In early COVID-19 studies, some evidence has been provided that electrolyte disorders may also be present upon patients' presentation, including sodium, potassium, chloride and calcium abnormalities

the aim of the study is Identification of elements that affect COVID-19 pathology to improve survival and decrease mortality rate.

Description:

SARS-CoV-2 invades human cells through binding angiotensin I converting enzyme 2 (ACE2) on the cell membrane. ACE2 is widely distributed in many types of human tissues, especially in the vital organs, such as heart, liver, kidney, and lungs. ACE2 is viewed as the principal counter-regulatory mechanism for the main axis of renin-angiotensin system (RAS) that is an essential player in the control of blood pressure and electrolyte balance. The final effect is to increase reabsorption of sodium and water, and thereafter increase blood pressure and excretion of potassium (K+). Besides, patients with COVID-19 often had gastrointestinal symptoms such as diarrhea and vomiting

Early studies proved that high percentage of COVID-19 patient were presented with electrolyte disorders, including sodium, potassium, chloride and calcium abnormalities. Such electrolyte disturbances have important implications not only for patient management but also for identifying potential pathophysiologic mechanisms underlying COVID-19 that could drive novel therapeutic opportunities

Recruitment information / eligibility

• Status: Completed
• Enrollment: 983
• Est. completion date: October 30, 2021
• Est. primary completion date: August 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients = 18 years old who were confirmed by the real-time PCR on the respiratory tract samples as positive of SARS-CoV-2.

Exclusion Criteria:

• Patients who had other causes of electrolyte disturbances (9):

• Chronic organ dysfunction (e.g., hepatic or renal dysfunction),

• Terminal cancer, immunodeficiency, and

• Patients with a history of long-term use of hormones & Diuretics were excluded.

Related Conditions & MeSH terms

• COVID-19
• Electrolyte Imbalance

Intervention

Other:
• electrolytes
measuring level of electrolytes

Locations

Country	Name	City	State
Egypt	Zagazig University	Zagazig

Sponsors (1)

Lead Sponsor	Collaborator
Zagazig University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	electrolytes disturbances in patients with COVID-19	Serum Electrolytes (Na, K, Ca, Cl, Ph, Mg) abnormality in COVID 19 patients laboratory results in the different stages of the disease	4 months
Secondary	To asses the relation of the electrolyte disturbances with the severity of COVID-19 infection.	To find any correlation between the level of the electrolyte disturbances and the morbidity and mortality of the disease .	4 months